Pepscan’s VEGF targetted vaccine study published in PNAS
Researchers of Pepscan have developed a peptide-based vaccine enabling a successful active anti-tumor immunization therapy targeting the growth hormone Vascular Endothelial Growth Factor (VEGF). The encouraging preclinical results have just been published in the reputable international journal PNAS (Proceedings of the National Academy of Sciences). VEGF is the pivotal growth factor for the formation of new blood vessels (angiogenesis). Targeting VEGF is a well established strategy to treat cancer, as demonstrated by the use of the monoclonal antibody bevacuzimab (Avastin®) …
Read more